官方 | W ■ 000 E Incyte 2021 Second Quarter Financial and Corporate Update AUGUST 3, 2021 FORWARD-LOOKING STATEMENTS 2 Except for the historical information set forth herein, the matters set forth in this presentation contain predictions, estimates, and other forward-looking statements, including without limitation statements regarding: the potential approval and launch of tafasitamab (Minjuvi®) in Europe and the potential growth opportunities represented by such potential launch, the recent positive CHMP opi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 INCYTE CORPORATION (Exact name of registrant as specified in its charter) Delaware 94-3136539 (State or other jurisdiction of incorporation or organization) 1801 Augustine ...

Incyte Corporation (NASDAQ:INCY) Q1 2021 Earnings Conference Call May 4, 2021 8:00 AM ET Company Participants Christine Chiou - Senior Director, Investor Relations Hervé Hoppenot - Chairman, President and Chief Executive Officer Barry Flannelly - General Manager, North America Steven Stein - Chief Medical Officer Christiana Stamoulis - Chief Financial Officer Conference Call Participants Marc Frahm - Cowen and Company Tazeen Ahmad - Bank of America Brian Abrahams - RBC Capital Markets Vikram Purohit - Morga ...

■ 官网 | 【国 e - - - - - - - - 000 0000000 Incyte 2021 First Quarter Financial and Corporate Update MAY 4, 2021 FORWARD-LOOKING STATEMENTS 2 Except for the historical information set forth herein, the matters set forth in this presentation contain predictions, estimates and other forward-looking statements, including without limitation statements regarding: our and our collaborators' potential new product approvals within the next 1-2 years and potential new indication launches; our ESG goals, including our go ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12400 INCYTE CORPORATION (Exact name of registrant as specified in its charter) Delaware 94-3136539 (State or ...

■ 000 ( 0 000 Incyte Data Highlights from Incyte's Adenosine Program from AACR 2021 = APRIL 12, 2021 FORWARD-LOOKING STATEMENTS 2 Except for the historical information set forth herein, the matters set forth in this presentation contain predictions, estimates and other forward-looking statements, including without limitation statements regarding: our expectations regarding our multiple opportunities for next generation immune-oncology therapies and the efficacy of our drug candidates and potential combinati ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12400 INCYTE CORPORATION (Exact name of registrant as specified in its charter) Delaware (State of other jurisdict ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 or FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12400 INCYTE CORPORATION (Exact name of registrant as specified in its charter) Delaware 94-3136539 (Stat ...

Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12400 INCYTE CORPORATION (Exact name of registrant as specified in its charter) Delaware 94-3136539 (State or ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12400 INCYTE CORPORATION (Exact name of registrant as specified in its charter) Delaware 94-3136539 (State or ...